Now that CMS has proposed paying hospitals significantly more to administer chimeric antigen receptor T-cell (CAR-T) treatments for cancer, hospitals are waiting to see whether state Medicaid programs and the commercial market follow suit. Medicare often influences private insurance pay rates and policies, and the next major update to the commercial market’s system for setting hospital pay rates is in October. On May 11, CMS proposed a national unadjusted pay rate for hospitals that administer CAR-T. The proposed MS-DRG (Medicare...